Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: Report of a case

Fumihiro Shoji, Daigo Kawano, Kensaku Ito, Yosuke Morodomi, Tokujiro Yano, Yoshihiko Maehara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We report a case of recurrent pulmonary adenocarcinoma, found 2 years after resection, which responded extremely well to erlotinib, after gefitinib treatment had failed to evoke any response. This case report provides useful information for thoracic oncologists and shows that we should consider giving erlotinib after gefitinib for recurrent pulmonary adenocarcinoma, even if the gefitinib treatment is ineffective.

Original languageEnglish
Pages (from-to)255-257
Number of pages3
JournalSurgery today
Volume41
Issue number2
DOIs
Publication statusPublished - Feb 1 2011

Fingerprint

Thorax
Therapeutics
Erlotinib Hydrochloride
Adenocarcinoma of lung
gefitinib
Oncologists

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib : Report of a case. / Shoji, Fumihiro; Kawano, Daigo; Ito, Kensaku; Morodomi, Yosuke; Yano, Tokujiro; Maehara, Yoshihiko.

In: Surgery today, Vol. 41, No. 2, 01.02.2011, p. 255-257.

Research output: Contribution to journalArticle

Shoji, Fumihiro ; Kawano, Daigo ; Ito, Kensaku ; Morodomi, Yosuke ; Yano, Tokujiro ; Maehara, Yoshihiko. / Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib : Report of a case. In: Surgery today. 2011 ; Vol. 41, No. 2. pp. 255-257.
@article{8988d66653bd46419bc738db8c35839c,
title = "Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: Report of a case",
abstract = "We report a case of recurrent pulmonary adenocarcinoma, found 2 years after resection, which responded extremely well to erlotinib, after gefitinib treatment had failed to evoke any response. This case report provides useful information for thoracic oncologists and shows that we should consider giving erlotinib after gefitinib for recurrent pulmonary adenocarcinoma, even if the gefitinib treatment is ineffective.",
author = "Fumihiro Shoji and Daigo Kawano and Kensaku Ito and Yosuke Morodomi and Tokujiro Yano and Yoshihiko Maehara",
year = "2011",
month = "2",
day = "1",
doi = "10.1007/s00595-009-4259-3",
language = "English",
volume = "41",
pages = "255--257",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib

T2 - Report of a case

AU - Shoji, Fumihiro

AU - Kawano, Daigo

AU - Ito, Kensaku

AU - Morodomi, Yosuke

AU - Yano, Tokujiro

AU - Maehara, Yoshihiko

PY - 2011/2/1

Y1 - 2011/2/1

N2 - We report a case of recurrent pulmonary adenocarcinoma, found 2 years after resection, which responded extremely well to erlotinib, after gefitinib treatment had failed to evoke any response. This case report provides useful information for thoracic oncologists and shows that we should consider giving erlotinib after gefitinib for recurrent pulmonary adenocarcinoma, even if the gefitinib treatment is ineffective.

AB - We report a case of recurrent pulmonary adenocarcinoma, found 2 years after resection, which responded extremely well to erlotinib, after gefitinib treatment had failed to evoke any response. This case report provides useful information for thoracic oncologists and shows that we should consider giving erlotinib after gefitinib for recurrent pulmonary adenocarcinoma, even if the gefitinib treatment is ineffective.

UR - http://www.scopus.com/inward/record.url?scp=79951650633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951650633&partnerID=8YFLogxK

U2 - 10.1007/s00595-009-4259-3

DO - 10.1007/s00595-009-4259-3

M3 - Article

C2 - 21264764

AN - SCOPUS:79951650633

VL - 41

SP - 255

EP - 257

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 2

ER -